FAQs

General

  • Zymeworks shares are traded on the New York Stock Exchange (NYSE) under the ticker symbol ZYME.
  • Our shares began trading on April 28, 2017.
  • The Company’s corporate headquarters is located at 1385 West 8th Avenue, Suite 540, Vancouver, BC V6H 3V9.
  • You can view the Company’s Board of Directors by visiting the Board of Directors page on the website.

  • You can view the Company’s management team by visiting the Management page on the website.

  • The Company’s fiscal year end is December 31.
  • The Company’s independent auditors are KPMG LLP.
  • The Company’s transfer agent is Computershare.

    You can contact Computershare via their website: www.computershare.com

    Written requests by regular mail can be made to:

    U.S. Investors:
    Computershare Investor Services
    P.O. Box 43078
    Providence, RI 02940-3078
    United States of America

    Canadian Investors:
    Computershare Investor Services
    100 University Ave., 8th Floor, North Tower
    Toronto, Ontario M5J 2Y1 Canada
    Telephone inquiries:
    1-800-564-6253 (toll free in Canada and the United States) between the hours of 8:30 a.m. and 8:00 p.m. Eastern Time or 514-982-7555 (international direct dial).

    Email: web.queries@computershare.com

  • The Company does not currently have a direct stock purchase plan.
  • The Company’s SEC filing can be accessed on the Financial Documents page of the investor relations portion of its website or can be accessed directly from the SEC’s website at www.sec.gov.

  • You can submit questions to the Zymeworks investor relations team by contacting ir@zymeworks.com or by submitting a request via the Contact Us page.

Voluntary Delisting from the TSX

  • Zymeworks applied to the Toronto Stock Exchange (“TSX”) to voluntarily delist its shares from the TSX, which is expected to become effective on October 1, 2019. Upon the effective date of delisting, the Company's shares will no longer be traded on this exchange. Zymeworks’ shares will still trade on the New York Stock Exchange (“NYSE”) under the symbol “ZYME”.
  • The Company believes the limited trading volume of its shares on the TSX no longer justifies the expense and administrative complexity of maintaining a dual listing. The Company's primary market for its shares will remain the NYSE.
  • No action is required. Zymeworks common shares which were listed on the TSX are the same shares as those listed on the NYSE and you may trade the common shares on the NYSE.
  • Yes, you will retain the same number of shares.
  • No, Zymeworks’ common shares continue to be listed and traded on the NYSE under the symbol of “ZYME.”
  • Zymeworks’ common shares can be purchased and sold on the NYSE. Most brokers in Canada maintain ready access to the NYSE to support you in this.
  • We understand that most brokers in Canada, including most discount brokers, have the ability to buy and sell securities listed on the NYSE. If your broker is unable to trade on the NYSE in order to trade your Zymeworks common shares you will need to open an account at a broker that is able to trade on NYSE.
  • Your shares will trade on the NYSE in US dollars, and if your account trades in a Canadian trading account, the value of your shares will be converted into Canadian dollars.